MMR & YF vaccines co-administered* | MMR or YF vaccine administered individually as first vaccine in a series* | Difference in seroconversion or p-value for comparison of antibody titers/ concentrations† | Interpretation | |
---|---|---|---|---|
Measles | MMR 1 YF 1 | MMR 1 YF 2 | ||
Intention-to-treat analysis | (n = 242) | (n = 245) | ||
Seroconversion | 97.9 (95.3–99.1) | 96.3 (93.2–98.1) | 1.6 (-1.5–4.7) | Co-administration is non-inferior to individual administration |
Antibody concentrations, mIU | 2024 (1705–2402) | 1638 (1323–2028) | 0.175 | No significant difference |
Per protocol analysis | (n = 203) | (n = 220) | ||
Seroconversion | 98.0 (95.0–99.2) | 96.4 (93.0–98.2) | 1.7 (-1.7–5.0) | Co-administration is non-inferior to individual administration |
Antibody concentrations, mIU | 1956 (1629–2348) | 1569 (1253–1964) | 0.188 | No significant difference |
Rubella | MMR 1 YF 1 | MMR 1 YF 2 | ||
Intention-to-treat analysis | (n = 241) | (n = 243) | ||
Seroconversion | 97.9 (95.2–99.1) | 94.7 (91.0–96.9) | 3.3 (-0.1–6.7) | Co-administration is non-inferior to individual administration |
Antibody concentrations, IU | 35.8 (31.5–40.7) | 40.8 (35.0–47.5) | 0.006 | Individual administration has higher concentrations |
Per protocol analysis | (n = 202) | (n = 218) | ||
Seroconversion | 97.5 (94.3–98.9) | 94.5 (90.6–96.8) | 3.0 (-0.7–6.8) | Co-administration is non-inferior to individual administration |
Antibody concentrations, IU | 32.2 (28.0–37.1) | 39.4 (33.5–46.3) | 0.001 | Individual administration has higher concentrations |
Mumps | MMR 1 YF 1 | MMR 1 YF 2 | ||
Intent-to-treat analysis | (n = 242) | (n = 243) | ||
Seroconversion | 96.7 (93.6–98.3) | 97.9 (95.3–99.1) | -1.3 (-4.1–1.6) | Co-administration is non-inferior to individual administration |
Antibody concentrations, U | 1807 (1470–2220) | 2252 (1877–2701) | 0.082 | No significant difference |
Per protocol analysis | (n = 203) | (n = 218) | ||
Seroconversion | 96.6 (93.1–98.3) | 98.2 (95.4–99.3) | -1.6 (-4.7–1.5) | Co-administration is non-inferior to individual administration |
Antibody concentrations, U | 1746 (1390–2192) | 2319 (1926–2792) | 0.037 | Individual administration has higher concentrations |
Yellow Fever | MMR 1 YF 1 | YF 1 MMR 2 | ||
Intention-to-treat analysis | (n = 244) | (n = 243) | ||
Seroconversion | 96.3 (93.1–98.1) | 97.5 (94.7–98.9) | -1.2 (-4.2–1.7) | Co-administration is non-inferior to individual administration |
Antibody titers | 219 (181–265) | 340 (283–408) | < 0.0001 | Individual administration has higher titers |
Per protocol analysis | (n = 205) | (n = 206) | ||
Seroconversion | 96.1 (92.5–98.0) | 98.1 (95.1–99.2) | -2.0 (-5.1–1.2) | Non-inferiority of co-administration not shown |
Antibody titers | 225 (181–279) | 373 (308–452) | < 0.0001 | Individual administration has higher titers |